Dr Pavlu is the clinical lead for acute leukaemia and myelodysplastic syndromes at Hammersmith Hospital, a leading haematological institute with a strong academic record in treating blood cancers.
His medical career started in 1998 and he has worked in leading haematology centres both here in the UK and abroad. He completed his haematological training at the Royal Free and Hammersmith Hospitals. Since then he has worked in the Imperial College NHS trust, providing consultant services to St. Mary’s and Hammersmith Hospitals.
In 2009 he became the clinical lead for acute leukaemia and has developed services at Hammersmith hospital in both clinical care and research. Dr Pavlu is the principal investigator on several acute leukaemia and transplantation trials.
He is also the stem cell transplantation clinical and collection facility director at Hammersmith Hospital. He is an inspector for the Joint Accreditation Committee for International Society for Cellular Therapy and European Society for Blood and Marrow Transplantation and ensures that centres maintain high levels of safety and quality when providing transplantation services.
Dr Pavlu’s broad training background and current specialised role means that he can provide the perfect combination of high-level diagnostics and individualised cutting-edge care.
QUALIFICATIONS, AFFILIATIONS AND SELECTED PUBLICATIONS
QUALIFICATIONS
MUDr First Faculty of Medicine, Charles University, Prague 1998
MD Charles University, Prague and St. George's Hospital, London 1998
MRCP (UK) Royal College of Physicians 2002
FRCPath Royal College of Pathologists 2007
AFFILIATIONS
American Society of Hematology
British Society for Blood and Marrow Transplantation
European Blood and Marrow Transplantation Society
Inspector for JACIE (international transplantation accreditation body)
Royal College of Physicians
Royal College of Pathologists
SELECTED PUBLICATIONS
Complete remission with incomplete count recovery (CRi) prior to allogeneic haematopoietic cell transplantation for acute myeloid leukaemia is associated with a high non-relapse mortality.
Leukemia 2020
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Journal of Hematology and Oncology 2019
Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.
Clinical Nutrition 2019
Fecal microbionta transplant: A novel biological approach to extensively drug-resistant organism-related non-relapse mortality.
Bone Marrow Transplantation 2017
Allogeneic Hematopoietic Cell Transplantation for Primary Refractory Acute Lymphoblastic Leukemia: A Report From the Acute Leukemia Working Party of the EBMT.
Cancer 2017
BKV-specific T-cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation.
European Journal of Haematology 2017
C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early and long-term mortality.
British Journal of Haematology 2016
Treatment and management of graft-versus-host disease: improving response and survival.
Therapeutic Advances in Hematology 2013
Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system.
British Journal of Haematology 2012
Three decades of transplantation for chronic myeloid leukemia: what have we learnt?
Blood 2011
Idiopathic cytopenia of undetermined significance and the minimal criteria for a diagnosis of myelodysplastic syndrome.
Leukemia & Lymphoma 2011
LACE-conditioned autologous stem cell transplantation for relapsed or refractory Diffuse Large B-cell Lymphoma: treatment outcome and risk factor analysis from a single centre.
Hematological Oncology 2011
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.
Blood 2010
Myocardial infarction in sickle-cell disease.
Lancet 2007
Pneumococcal septicaemia.
Lancet Infectious Diseases 2007
Dual inhibition of ras and bcr-abl signaling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
British Journal of Haematology 2007
Pathological odontoid fracture.
Lancet Oncology 2006
Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib.
Lancet Oncol. 2005
Superwarfarin poisoning.
Lancet 2005
Roth’s Spots.
New England Journal of Medicine 2005
Paroxysmal nocturnal haemoglobinuria due to an 88 bp direct tandem repeat insertion in the PIG-A gene.
British Journal of Haematology 1997
For full list of publications available through Imperial College London please click here.